Business Information
The group's principal activities are to develop, manufacture and distribute therapeutic products and devices. The products promote the protection and healing of bone, cartilage and soft tissue. The group's products include orthovisc (R), which is based on hyaluronic acid (ha), used in the treatment of some forms of osteoarthritis in humans, and hyvisc (R), used in the treatment of equine osteoarthritis. Orthovisc(R) is currently marketed in Canada, parts of Europe, turkey and Israel. The group also manufactures amvisc(R) and amvisc(R) plus for bausch & lomb, which are used as viscoelastic supplements in ophthalmic surgery.
|
|
Name |
Title
|
Email
|
| Kevin Quinlan | CFO, Principal Financial Officer | N/A | | William Mrachek | VP - Human Resources | N/A | | Charles Sherwood | Dir., CEO, Pres. | N/A | | Eugene Davidson | Dir. | N/A | | John Moran | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 26,841 | 4,604 | | 2005 | 29,835 | 5,893 | | 2004 | 26,466 | 11,190
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
